Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), with respect to the proportion of subjects with sustained virologic response (SVR) 24 weeks after the planned end of treatment (SVR24).
Inclusion criteria
- Hepatitis C Virus (HCV) in treatment naïve patients